Following Pivotal Trial, FDA Set to Review First-of-a-Kind VR Autism Therapy

WASHINGTON, April 20, 2026 /PRNewswire/ -- Floreo, a developer of virtual reality (VR)-based therapeutic technologies, today announced the submission of a De Novo request to the U.S. Food and Drug Administration (FDA) for FloreoRx, its software-based product being evaluated for use in...